Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 9/20 | 0.46 |
| ▸ | AHR | P35869 | 5/20 | 0.44 |
| ▸ | CMA1 | P23946 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isobutyramide SCHEMBL17099544 | 0.85 | TDP2 (0.36) | TDP2AHRCMA1GRIA1CACNG8 | |
| SCHEMBL13726349 | 0.84 | KIF11 (0.46) | TDP2KIF11MEN1KMT2A | |
| SCHEMBL1318667 | 0.81 | TGM2 (0.44) | TDP2AHRCMA1GRIA1CACNG8 | |
| SCHEMBL5373768 | 0.81 | TDP2 (0.49) | TDP2AHRCMA1PDK2EIF2AK2 | |
| SCHEMBL27076383 | 0.81 | MEN1 (0.39) | TDP2AHRCMA1KIF11MEN1 | |
| SCHEMBL27076357 | 0.80 | ABCC9 (0.33) | TDP2AHRCMA1KIF11MEN1 | |
| SCHEMBL5498437 | 0.78 | GRIA1 (0.41) | TDP2AHRCMA1GRIA1CACNG8 | |
| SCHEMBL1163094 | 0.78 | GRIA1 (0.41) | TDP2AHRCMA1GRIA1CACNG8 | |
| SCHEMBL20112858 | 0.78 | TDP2 (0.46) | TDP2AHRCMA1GRIA1CACNG8 | |
| SCHEMBL18189576 | 0.78 | AHR (0.53) | TDP2AHRCMA1GRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-19 | — | — | US | disclosed |
| EP-4460498-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-12 | — | — | US | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | TDP2 3010/4885AHR 2068/4885CMA1 4614/4885 |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | TDP2 3010/4885AHR 2068/4885CMA1 4614/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | TDP2 2496/4885AHR 409/4885CMA1 3480/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | TDP2 2249/4885AHR 3497/4885CMA1 3601/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | TDP2 2839/4885AHR 2935/4885CMA1 2766/4885 |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | MAP3K20, MAP3K8, PRKACA | TDP2 1175/4885AHR 3634/4885CMA1 2999/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | TDP2 1247/4885AHR 574/4885CMA1 3794/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | TDP2 3010/4885AHR 2068/4885CMA1 4614/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | TDP2 3128/4885AHR 2063/4885CMA1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.